Indications and Purposes
| 1 Indications And Usage Talzenna Is Indicated For The Treatment Of Adult Patients With Deleterious Or Suspected Deleterious Germline Breast Cancer Susceptibility Gene (brca)-Mutated ( Gbrcam ) Human Epidermal Growth Factor Receptor 2 (her2)-Negative Locally Advanced Or Metastatic Breast Cancer. Select Patients For Therapy Based On An Fda-Approved Companion Diagnostic For Talzenna [see Dosage And Administration (2.1) ] . Talzenna Is A Poly (adp-Ribose) Polymerase (parp) Inhibitor Indicated For The Treatment Of Adult Patients With Deleterious Or Suspected Deleterious Germline Brca-Mutated ( Gbrcam ) Her2-Negative Locally Advanced Or Metastatic Breast Cancer. Select Patients For Therapy Based On An Fda-Approved Companion Diagnostic For Talzenna. ( 1 ) |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Talazoparib Tosylate |
|
ZINC6427042 |